ASCLETIS-B (01672) Presents Full Analysis of ASC30 Oral Tablet Ib Study, ASC30 Injection Ib Study, and ASC31/ASC47 Combination Preclinical Research at ObesityWeek® 2025

Stock News

Nov 05

ASCLETIS-B (01672) announced multiple poster presentations at ObesityWeek® 2025 in Atlanta, Georgia, including the full analysis of the once-daily ASC30 oral tablet Ib study, the monthly ASC30 injection Ib study, and preclinical research on the ASC31/ASC47 combination therapy.

"These presentations highlight the promising efficacy and safety profile of ASCLETIS' diversified small-molecule and peptide obesity pipeline, demonstrating the strength of our proprietary structure-based AI-assisted drug discovery (AISBDD) and ultra-long-acting platform (ULAP)," said Dr. Jinzi Wu, Founder, Chairman, and CEO of ASCLETIS.

"While advancing the clinical development of ASC30, ASC31, and ASC47, we remain focused on strategic partnerships to better address the global unmet needs of obesity patients."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1153422057"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1153422057\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1153422057?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 08:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153422057","market":"sg","top_or_hot":-1,"title":"ASCLETIS-B (01672) Presents Full Analysis of ASC30 Oral Tablet Ib Study, ASC30 Injection Ib Study, and ASC31/ASC47 Combination Preclinical Research at ObesityWeek® 2025","media":"Stock News","content":"<p>ASCLETIS-B (01672) announced multiple poster presentations at ObesityWeek® 2025 in Atlanta, Georgia, including the full analysis of the once-daily ASC30 oral tablet Ib study, the monthly ASC30 injection Ib study, and preclinical research on the ASC31/ASC47 combination therapy.</p>\n<p>\"These presentations highlight the promising efficacy and safety profile of ASCLETIS' diversified small-molecule and peptide obesity pipeline, demonstrating the strength of our proprietary structure-based AI-assisted drug discovery (AISBDD) and ultra-long-acting platform (ULAP),\" said Dr. Jinzi Wu, Founder, Chairman, and CEO of ASCLETIS.</p>\n<p>\"While advancing the clinical development of ASC30, ASC31, and ASC47, we remain focused on strategic partnerships to better address the global unmet needs of obesity patients.\"</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ASCLETIS-B (01672) Presents Full Analysis of ASC30 Oral Tablet Ib Study, ASC30 Injection Ib Study, and ASC31/ASC47 Combination Preclinical Research at ObesityWeek® 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nASCLETIS-B (01672) Presents Full Analysis of ASC30 Oral Tablet Ib Study, ASC30 Injection Ib Study, and ASC31/ASC47 Combination Preclinical Research at ObesityWeek® 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-05 08:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ASCLETIS-B (01672) announced multiple poster presentations at ObesityWeek® 2025 in Atlanta, Georgia, including the full analysis of the once-daily ASC30 oral tablet Ib study, the monthly ASC30 injection Ib study, and preclinical research on the ASC31/ASC47 combination therapy.</p>\n<p>\"These presentations highlight the promising efficacy and safety profile of ASCLETIS' diversified small-molecule and peptide obesity pipeline, demonstrating the strength of our proprietary structure-based AI-assisted drug discovery (AISBDD) and ultra-long-acting platform (ULAP),\" said Dr. Jinzi Wu, Founder, Chairman, and CEO of ASCLETIS.</p>\n<p>\"While advancing the clinical development of ASC30, ASC31, and ASC47, we remain focused on strategic partnerships to better address the global unmet needs of obesity patients.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"","article_id":"1153422057","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153422057","pubTimestamp":1762301654,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ASCLETIS-B (01672) announced multiple poster presentations at ObesityWeek® 2025 in Atlanta, Georgia, including the full analysis of the once-daily ASC30 oral tablet Ib study, the monthly ASC30...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","01477":"欧康维视生物-B","BK1191":"制药","01672":"歌礼制药-B","BK1515":"抗疫概念","BK1161":"生物科技"},"translate_title":"歌礼-B（01672）在ObesityWeek上展示了ASC30口服片剂Ib研究、ASC30注射液Ib研究和ASC31/ASC47联合临床前研究的完整分析®2025","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":1,"01672":1},"content_text":"ASCLETIS-B (01672) announced multiple poster presentations at ObesityWeek® 2025 in Atlanta, Georgia, including the full analysis of the once-daily ASC30 oral tablet Ib study, the monthly ASC30 injection Ib study, and preclinical research on the ASC31/ASC47 combination therapy.\n\"These presentations highlight the promising efficacy and safety profile of ASCLETIS' diversified small-molecule and peptide obesity pipeline, demonstrating the strength of our proprietary structure-based AI-assisted drug discovery (AISBDD) and ultra-long-acting platform (ULAP),\" said Dr. Jinzi Wu, Founder, Chairman, and CEO of ASCLETIS.\n\"While advancing the clinical development of ASC30, ASC31, and ASC47, we remain focused on strategic partnerships to better address the global unmet needs of obesity patients.\"","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}